Kennedy Capital Management, Inc. Ardelyx, Inc. Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $266,579 - $526,959	-309,976 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $936,701 - $6.03 Million	-737,560 Reduced 70.41%	309,976 $409,000
Q2 2021 Aug 16, 2021	BUY	$6.55 - $8.98 $1.54 Million - $2.11 Million	234,931 Added 28.91%	1,047,536 $7.94 Million
Q1 2021 May 14, 2021	BUY	$6.1 - $7.69 $4.96 Million - $6.25 Million	812,605 New	812,605 $5.38 Million
Q1 2018 May 14, 2018	SELL	$5.05 - $7.9 $638,446 - $998,757	-126,425 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$4.85 - $7.8 $575,083 - $924,877	-118,574 Reduced 48.4%	126,425 $834,000
Q3 2017 Nov 13, 2017	BUY	$4.35 - $5.7 $1.07 Million - $1.4 Million	244,999	244,999 $1.37 Million

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $787M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.